Turning to the acute phase of MI, several recent clinical trials have explored the impact of SGLT2 inhibitors when initiated shortly after AMI, yielding conflicting results regarding their effects on NT-proBNP concentrations. The gene discussed is NPPB; the disease is myocardial infarction.